- Home
- PAVM vs NXTC Comparison
PAVM vs NXTC Comparison
Compare PAVM & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- NXTC
- Stock Information
- Founded
- PAVM 2014
- NXTC 2015
- Country
- PAVM United States
- NXTC United States
- Employees
- PAVM N/A
- NXTC N/A
- Industry
- PAVM Medical/Dental Instruments
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- NXTC Health Care
- Exchange
- PAVM Nasdaq
- NXTC Nasdaq
- Market Cap
- PAVM 12.0M
- NXTC 13.9M
- IPO Year
- PAVM 2016
- NXTC 2019
- Fundamental
- Price
- PAVM $0.59
- NXTC $5.26
- Analyst Decision
- PAVM Strong Buy
- NXTC Strong Buy
- Analyst Count
- PAVM 1
- NXTC 3
- Target Price
- PAVM $19.00
- NXTC $33.00
- AVG Volume (30 Days)
- PAVM 115.2K
- NXTC 27.2K
- Earning Date
- PAVM 08-11-2025
- NXTC 07-31-2025
- Dividend Yield
- PAVM N/A
- NXTC N/A
- EPS Growth
- PAVM N/A
- NXTC N/A
- EPS
- PAVM 0.96
- NXTC N/A
- Revenue
- PAVM $1,993,000.00
- NXTC N/A
- Revenue This Year
- PAVM N/A
- NXTC N/A
- Revenue Next Year
- PAVM $455.63
- NXTC N/A
- P/E Ratio
- PAVM $0.62
- NXTC N/A
- Revenue Growth
- PAVM N/A
- NXTC N/A
- 52 Week Low
- PAVM $0.54
- NXTC $2.69
- 52 Week High
- PAVM $1.90
- NXTC $20.76
- Technical
- Relative Strength Index (RSI)
- PAVM 44.90
- NXTC 49.02
- Support Level
- PAVM $0.58
- NXTC $4.75
- Resistance Level
- PAVM $0.62
- NXTC $5.23
- Average True Range (ATR)
- PAVM 0.03
- NXTC 0.50
- MACD
- PAVM 0.00
- NXTC 0.03
- Stochastic Oscillator
- PAVM 55.90
- NXTC 47.14
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.